Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 1.19%43.92B | -0.35%10.93B | 0.27%11.72B | -0.55%10.57B | 5.74%10.7B | 4.84%43.41B | 5.66%10.97B | 8.19%11.69B | 4.57%10.63B | 0.67%10.11B |
Cost of revenue | -0.30%37.43B | -0.54%9.45B | -2.02%9.82B | -2.40%9.03B | 4.13%9.13B | 8.35%37.54B | 6.70%9.5B | 11.72%10.02B | 8.81%9.26B | 6.02%8.77B |
Gross profit | 10.73%6.49B | 0.88%1.49B | 14.10%1.9B | 11.77%1.54B | 16.32%1.56B | -13.18%5.86B | -0.61%1.48B | -9.11%1.67B | -17.06%1.38B | -24.31%1.34B |
Operating expense | -2.76%5.72B | -11.44%1.39B | -0.14%1.48B | 4.01%1.45B | -2.52%1.39B | -3.19%5.88B | 3.76%1.57B | -6.09%1.48B | -6.63%1.4B | -3.77%1.43B |
Staff costs | -6.05%2.28B | -7.73%585M | -4.36%570M | -4.36%571M | -7.65%555M | -9.17%2.43B | -3.79%634M | -11.44%596M | -11.95%597M | -9.35%601M |
Selling and administrative expenses | 0.43%1.4B | -5.17%330M | 2.11%387M | 3.31%343M | 1.48%343M | 0.79%1.4B | 3.88%348M | 1.34%379M | -3.49%332M | 1.50%338M |
-General and administrative expense | 0.43%1.4B | -5.17%330M | 2.11%387M | 3.31%343M | 1.48%343M | 0.79%1.4B | 3.88%348M | 1.34%379M | -3.49%332M | 1.50%338M |
Depreciation and amortization | -14.52%265M | -11.69%68M | -12.82%68M | -15.38%66M | -18.18%63M | -1.27%310M | -3.75%77M | -1.27%78M | 0.00%78M | 0.00%77M |
-Depreciation | -14.52%265M | -11.69%68M | -12.82%68M | -15.38%66M | -18.18%63M | -1.27%310M | -3.75%77M | -1.27%78M | 0.00%78M | 0.00%77M |
Other operating expenses | 1.38%1.77B | -20.19%411M | 6.07%454M | 21.39%471M | 4.61%431M | 2.59%1.74B | 16.25%515M | -5.10%428M | -1.52%388M | 0.24%412M |
Operating profit | 4,652.94%774M | 196.94%95M | 127.42%423M | 557.89%87M | 296.51%169M | -102.50%-17M | -206.25%-98M | -27.63%186M | -111.52%-19M | -129.76%-86M |
Net non-operating interest income (expenses) | 57.14%-9M | -116.67%-1M | 40.00%-6M | 150.00%4M | 33.33%-6M | 32.26%-21M | 185.71%6M | -25.00%-10M | 0.00%-8M | -12.50%-9M |
Non-operating interest income | 42.86%20M | -53.85%6M | --2M | 1,000.00%11M | --1M | 600.00%14M | 1,200.00%13M | --0 | 0.00%1M | --0 |
Non-operating interest expense | -17.14%29M | 0.00%7M | -20.00%8M | -22.22%7M | -22.22%7M | 6.06%35M | -12.50%7M | 25.00%10M | 0.00%9M | 12.50%9M |
Net investment income | 90.28%274M | 100.33%15M | -98.86%52M | 262.50%29M | 85.42%178M | 7.46%144M | -19,595.65%-4.53B | 3,260.29%4.57B | 130.77%8M | 104.26%96M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -95.79%195M | -97.95%94M | 118.45%19M | -115.63%-10M | 3.37%92M | 2,725.61%4.63B | 6,741.79%4.58B | -10,200.00%-103M | -16.88%64M | 323.81%89M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | 94.10%-123M | 94.75%-107M | 44.44%-5M | 0.00%-6M | 82.14%-5M | -4,528.89%-2.08B | -16,900.00%-2.04B | -80.00%-9M | 57.14%-6M | -100.00%-28M |
Less:Other special charges | -30.11%123M | -19.55%107M | -44.44%5M | 0.00%6M | -82.14%5M | 238.46%176M | 600.00%133M | 80.00%9M | -57.14%6M | 100.00%28M |
Less:Write off | --0 | ---- | ---- | ---- | ---- | 27,342.86%1.91B | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | -64.29%35M | -240.00%-14M | -33.33%16M | -70.37%16M | 70.00%17M | 122.73%98M | -44.44%10M | 71.43%24M | 1,250.00%54M | 25.00%10M |
Income before tax | -58.57%1.14B | 103.86%80M | -89.35%496M | 25.53%118M | 564.18%445M | 191.21%2.75B | -16,023.08%-2.07B | 1,082.23%4.66B | -53.23%94M | -80.06%67M |
Income tax | -78.00%238M | 85.42%-21M | -92.91%84M | 208.33%37M | 375.86%138M | 385.20%1.08B | -323.53%-144M | 811.54%1.19B | 400.00%12M | -77.86%29M |
Net income | -46.01%900M | 105.19%100M | -88.13%412M | -1.20%82M | 727.03%306M | 131.53%1.67B | -4,195.74%-1.93B | 1,215.15%3.47B | -59.51%83M | -81.86%37M |
Net income continuous operations | -45.95%901M | 105.24%101M | -88.14%412M | -1.22%81M | 707.89%307M | 131.21%1.67B | -4,197.87%-1.93B | 1,215.53%3.47B | -60.00%82M | -81.46%38M |
Noncontrolling interests | -9.52%19M | -45.45%6M | 100.00%8M | -87.50%1M | 300.00%4M | 520.00%21M | 1,000.00%11M | 200.00%4M | 260.00%8M | -166.67%-2M |
Net income attributable to the company | -46.44%881M | 104.90%95M | -88.38%403M | 12.33%82M | 652.50%301M | 126.90%1.65B | -4,310.87%-1.94B | 1,194.40%3.47B | -65.40%73M | -80.00%40M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -46.44%881M | 104.90%95M | -88.38%403M | 12.33%82M | 652.50%301M | 126.90%1.65B | -4,310.87%-1.94B | 1,194.40%3.47B | -65.40%73M | -80.00%40M |
Gross dividend payment | ||||||||||
Basic earnings per share | -46.49%335.78 | 104.85%35.85 | -88.37%153.86 | 10.24%30.9 | 647.37%115.17 | 126.71%627.47 | -4,312.78%-738.5 | 1,193.93%1.32K | -65.19%28.03 | -79.86%15.41 |
Diluted earnings per share | -46.49%335.78 | 104.84%35.7211 | -88.38%153.702 | 11.01%30.9 | 647.37%115.17 | 126.71%627.47 | -4,314.09%-738.7293 | 1,194.32%1.32K | -65.40%27.8364 | -79.86%15.41 |
Dividend per share | 0.00%80 | 0.00%40 | 0 | 0.00%40 | 0 | 0.00%80 | 0.00%40 | 0 | 0.00%40 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |